Marinus Pharmaceuticals (MRNS) shares were up premarket Monday after the company said it signed a deal under which Immedica Pharma will acquire all issued and outstanding shares for $0.55 a share.
Under the terms of the deal, Immedica Pharma will initiate a cash tender offer for all MRNS shares, corresponding to an implied enterprise value of $151 million, the companies said.
The companies said they intend to close the transaction in Q1 and that Marinus' board of directors unanimously approved the merger plan.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。